Supreme Court ruling sets stage for renewed US fight over drug patents
A timely US House Judiciary IP subcommittee hearing this week underscored the divide over the ability — and some say obligation — of Congress to speed cheaper generic and biosimilar drugs...To view the full article, register now.
Already a subscriber? Click here to view full article